Categories Earnings, Health Care

Sanofi (NASDAQ: SNY): Q3 2019 Earnings Snapshot

— Generic drugmaker Sanofi (NASDAQ: SNY) reported net income of EUR 1.77 billion or EUR 1.49 per share for the third quarter, on IFRS basis, down 23.% and 18.6% respectively from last year

— IFRS net sales increased 1.1% year-over-year to EUR 9.5 billion, on a reported basis

— Sanofi Genzyme sales rose 19.5% annually, aided by continued strong uptake of Dupixent

— Vaccine sales decreased 9.8%, reflecting anticipated weighing of flu vaccine supply towards year-end

— Expects business earnings to grow about 5%, on a constant-currency basis and excluding one-off items, in fiscal 2019

— During the quarter, European Commission approved Dupixent for severe chronic rhinosinusitis

— Achieved positive results from advanced-stage study on Dupixent for severe atopic dermatitis in children

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips

Most Popular

Should investors worry about Micron’s (MU) weak Q4 results and guidance?

The semiconductor industry is a rapidly growing business segment that currently thrives on the digital transformation wave. The demand for memory chips and other semiconductor products increased over the years,

What has Bed Bath & Beyond (BBBY) outlined for this fiscal year?

Shares of Bed Bath & Beyond (NASDAQ: BBBY) were up on Friday, a day after the company delivered disappointing results for the second quarter of 2022. The company reported a

NKE Earnings: Highlights of Nike’s Q1 2023 results

Nike, Inc. (NYSE: NKE) has reported a decrease in net profit for the first quarter of 2023, despite a modest increase in revenues. The company's stock suffered a big loss

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top